SARcode Biosciences sarcode.com


Public lists: Eye Health (691)

SARcode is a private, San Francisco based biotechnology company focused on the development of small molecule LFA-1 antagonists to treat inflammatory diseases. Targets include topical therapies for T-cell mediated, ophthalmic and dermatologic diseases including dry eye, diabetic retinopathy, eczema and psoriasis. In March 2013, SARcode Biosciences was acquired by Shire. The valuation of SARcode Biosciences was $160 million.. Other terms of the deal were not released.

SARcode is a private, San Francisco based biotechnology company focused on the development of small molecule LFA-1 antagonists to treat inflammatory diseases. Targets include topical therapies for T-cell mediated, ophthalmic and dermatologic diseases...Show all

Company (Acquired)

Phone: 650-416-7560

Fax:

1000 Marina Blvd
Suite 250
Brisbane, 94005
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
SARcode Biosciences $73.2M Mar 25, 2013
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related SARcode Biosciences Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 5 investors

Competitors

Company Status Description Investors

Catalyst Biosciences

South San Francisco, California, United States
MergedCatalyst Biosciences is developing next generation biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase therapeutics. Catalyst is focusing its product development efforts on drug candidates for...Show allLogin to see details

TaiGen Biotechnology

Taipei, Taiwan
IPO / Went publicTaiGen Biotechnology is a research-based and product-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases, cancer and diabetes-related complications. TaiGen has a wholly-owned Beijing subsidiary with a proven capacity to conduct clinical trials and related registrations.Login to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Crystalline pharmaceutical and methods of preparation and use thereof May 03, 2016 Feb 13, 2018 Patent
Continuous flow carboxylation reaction Sep 25, 2015 Aug 08, 2017 Patent
Lfa-1 inhibitor and methods of preparation and polymorph thereof Jun 23, 2015 Jul 18, 2017 Patent
Compositions and methods for treatment May 12, 2014 Jun 09, 2015 Patent
Compositions and methods for treatment May 12, 2014 Jun 02, 2015 Patent
See all 42 patents